BCL2L11 (BIM) is a pro-apoptotic BH3-only protein that serves as a major determinant for initiating the intrinsic apoptotic pathway under both physiological and pathophysiological conditions 1. The gene produces multiple alternatively spliced isoforms with varying pro-apoptotic potentials, with BimL being more potent than BimEL in inducing apoptosis and anoikis 1. BCL2L11 functions through tight regulation at transcriptional, translational, and post-translational levels, ensuring timely activation of apoptosis 1. In disease contexts, BCL2L11 plays crucial roles in cancer biology, where tumor cells often develop mechanisms to suppress its expression for progression and metastasis 1. Genetic variants in BCL2L11 are associated with increased risk of B-cell non-Hodgkin lymphoma 2. The gene is regulated by multiple microRNAs including miR-885 in cardiomyocytes 3, miR-300 in papillary thyroid cancer 4, and miR-30a-5p in multiple myeloma 5. In therapeutic contexts, BCL2L11 mediates apoptosis in melanoma cells when TGFβ signaling is combined with MAPK pathway inhibition 6. Under physiological conditions, proper BCL2L11 regulation is essential for immune system homeostasis, with dysregulation leading to autoimmunity or impaired immune responses 1.